Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J

This article was originally published in The Tan Sheet

Executive Summary

McNeil consumer franchise generated "modest" 2% sales growth - primarily in the U.S. -during Q3, although prescription COX-2 inhibitors continue to negatively affect Tylenol sales, firm says in Oct. 16 analysts call. Reintroduction of St. Joseph aspirin for adult cardiotherapy, acquisition of Viactiv calcium chews from Mead Johnson were "positive contributors" to growth. J&J worldwide consumer sales rose 3.2% to $1.78 bil., including negative currency impact, with skin care sales up 10% operationally. Consolidated sales jumped 10.8% to $8.24 bil., with net earnings of $1.53 bil., a 15.6% swell
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS093173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel